The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease
Abstract
The management of fluctuations in motor function complicating advanced Parkinson's disease with continuously administered dopaminomimetics was studied in 12 patients. In response to 7 to 12 days of round‐the‐clock intravenous infusions of levodopa, fluctuations in motor performance gradually diminished, ultimately by more than 40°. The beneficial effect persisted for about 6 days after withdrawal of continuous parenteral treatment and resumption of standard oral therapy. Clinical improvement was associated with changes in several pharmacological indices: Acute dose‐response studies of intravenous levodopa showed a shift of the curve to the right in the immediate postinfusion phase compared to preinfusion studies; the therapeutic index improved significantly as patients demonstrated about 76° increased beneficial antiparkinsonian response with an equal degree of toxic dyskinetic effects; and the duration of action levodopa was prolonged by 30°. These results suggest that changes in central dopaminergic mechanisms contributing to motor complications in advanced Parkinson's disease can be modified by procedures that provide continuous dopamine replacement. Presumably these modifications underlie the gradual amelioration of motor fluctuations over several days of round‐the‐clock therapy. Results of the present study also suggest potential deleterious effects of chronic intermittent oral treatment in the development of motor complications and thus support the role of long‐term, continuous administration of dopaminomimetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Cited by
Long-term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease
Hauser, R. A., Freeman, T. B., Snow, B. J., Nauert, M., Gauger, L., Kordower, J. H., & Olanow, C. W. (1999) · Archives of Neurology · doi:10.1001/archneur.56.2.179 · Cited by 353
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
The response to levodopa in parkinson's disease: Imposing pharmacological law and order
Nutt, J. G., & Holford, N. H. G. (1996) · Annals of Neurology · doi:10.1002/ana.410390504 · Cited by 299
Levodopa in the treatment of Parkinson's disease
Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02697.x · Cited by 231
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies
Thanvi, B. R., & Lo, T. C. N. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2003.013912 · Cited by 194
Metadata
- Authors
- Mouradian, M. M., Heuser, I. J. E., Baronti, F., & Chase, T. N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1990-01
- Volume
- 27
- Issue
- 1
- Pages
- 18-23
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2010723753
- Cited by
- 236
- References
- 1
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. https://app.cochat.ai/papers/10.1002/ana.410270105
- The paper
- Mouradian, M. M., Heuser, I. J. E., Baronti, F., & Chase, T. N. (1990). Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Annals of Neurology. https://doi.org/10.1002/ana.410270105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.